HEMLIBRA

Aug 22, 2025

Over the past four decades, hemophilia A treatment has advanced remarkably. Beginning with the introduction of cryoprecipitate in 1964, treatment progressed to plasma-derived FVIII, then to recombinant FVIII therapies in the 1980s. The 1990s and 2000s saw the rise of Standard Half-life (SHL) products, followed by E...

Jun 10, 2025

CAR-T cell therapy has revolutionized the treatment of blood cancers, earning regulatory approval and delivering impressive results in hematologic malignancies. However, its success has not yet translated to solid tumors, where it continues to face significant challenges and limited long-term efficacy. As a result,...

Jul 14, 2023

Hemophilia A is a rare genetic bleeding disorder that primarily affects males. Hemophilia A is the most common type of hemophilia, accounting for approximately 80% of all cases. It is estimated to occur in about 1 in 5,000 to 10,000 male births. As per the Centers for Disease Control (CDC) (2020), the estimated pre...

Nov 07, 2022

Hemophilia A treatment scenario before the launch of HEMLIBRA Despite the ups and downs throughout history, the management of hemophilia A patients substantially improved over the past 40 years. The groundbreaking discovery of cryoprecipitate in 1964 marked the beginning of the modern progression of hemophilia t...